Biochemistry of Cardiovascular Dysfunction in Obesity
BücherAngebote / Angebote:
Obesity is an independent risk factor for cardiovascular disease (CVD) in adults as well as in obese children. This book will provide a description of the impact of obesity on the cardiovascular system and increased predisposition to CVD. It will identify the major biochemical mechanisms that lead to the occurrence of myocardial abnormalities and vascular alterations in obesity. We will also have some discussion on the biochemistry of the so-called obesity paradox in relation to CVD. The contributors to this book are international experts on obesity and associated cardiovascular complications. This book is also uniquely positioned as it focuses on the biochemistry of obesity-induced cardiovascular dysfunction. There are 20 chapters in 2 different parts in this book, comprising of Part A: Pathophysiology of Cardiovascular Complications in Obesity (11 chapters) and Part B: Modification of Cardiovascular Dysfunction in obesity (9 chapters). The intent of this volume is to provide current and basic understanding of the biochemical mechanisms of obesity induced cardiovascular dysfunction that will be of value not only to cardiologists and other allied health professionals, but will also stimulate and motivate biomedical researchers and scientists to find the way to prevent the epidemic of obesity associated cardiovascular abnormalities. Furthermore, this book will serve as a highly useful resource for medical students, fellows, residents and graduate students with an interest in the cardiovascular system.
In summary, this book covers a broad range of biochemical mechanisms of obesity-induced cardiovascular complications. We hope that the reader will understand that obesity is linked to an increase in the risk and occurrence of fatal CVD. Furthermore, the underlying message presented in the book is that the cause of obesity related disorders is complex and that understanding the biochemistry of cardiovascular dysfunction may contribute to the development of novel interventions for the prevention and treatment of obesity associated comorbidities.
Folgt in ca. 15 Arbeitstagen